MedTrace Logo

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT07416474 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 574

Last updated 2026-04-20

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.

Conditions

Interventions

DRUG

RC148 plus Carboplatin and Paclitaxel

RC148, Carboplatin, Paclitaxel

DRUG

Tislelizumab plus Carboplatin and Paclitaxel

Tislelizumab, Carboplatin, Paclitaxel

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-03
Primary Completion
2027-12-31
Completion
2029-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07416474 on ClinicalTrials.gov